Literature DB >> 15050865

Compromised late-stage motion processing in schizophrenia.

Yue Chen1, Deborah L Levy, Summer Sheremata, Philip S Holzman.   

Abstract

BACKGROUND: Visual motion processing is compromised in schizophrenia, as shown in deficient velocity discrimination. Processing of motion signals comprises progressive stages along the geniculate-striate-extrastriate-cortex pathway. Based on neurophysiologic and brain lesion studies, a velocity discrimination deficit can implicate early-stage motion processing if it is contrast-dependent or late-stage motion processing if it is contrast-independent.
METHODS: To determine which stage underlies the deficient velocity discrimination in schizophrenia, we examined the effects of visual contrast on velocity discrimination. We measured velocity discrimination thresholds in schizophrenia patients (n = 34) and normal control subjects (n = 17) at both low and high contrasts, using each subject's contrast detection threshold to equate contrast levels.
RESULTS: Schizophrenia patients showed poor velocity discrimination that improved little with high contrast, whereas normal control subjects showed enhanced velocity discrimination with increased contrast.
CONCLUSIONS: The finding that the velocity discrimination deficit in schizophrenia is independent of contrast modulation implicates the later, rather than the earlier, stages of motion processing, which is mediated in the extrastriate cortex.

Entities:  

Mesh:

Year:  2004        PMID: 15050865     DOI: 10.1016/j.biopsych.2003.12.024

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  36 in total

1.  Early-stage visual processing deficits in schizophrenia.

Authors:  Pamela D Butler; Daniel C Javitt
Journal:  Curr Opin Psychiatry       Date:  2005-03       Impact factor: 4.741

2.  Schizophrenia patients show augmented spatial frame illusion for visual and visuomotor tasks.

Authors:  Y Chen; R McBain; D Norton; D Ongur
Journal:  Neuroscience       Date:  2010-10-30       Impact factor: 3.590

3.  Magnocellular contributions to impaired motion processing in schizophrenia.

Authors:  Dongsoo Kim; Glenn Wylie; Roey Pasternak; Pamela D Butler; Daniel C Javitt
Journal:  Schizophr Res       Date:  2005-12-01       Impact factor: 4.939

4.  Eye movement and visual motion perception in schizophrenia II: Global coherent motion as a function of target velocity and stimulus density.

Authors:  Walter L Slaghuis; Tina Holthouse; Amy Hawkes; Raimondo Bruno
Journal:  Exp Brain Res       Date:  2007-06-14       Impact factor: 1.972

Review 5.  Eye tracking dysfunction in schizophrenia: characterization and pathophysiology.

Authors:  Deborah L Levy; Anne B Sereno; Diane C Gooding; Gilllian A O'Driscoll
Journal:  Curr Top Behav Neurosci       Date:  2010

Review 6.  Abnormal visual motion processing in schizophrenia: a review of research progress.

Authors:  Y Chen
Journal:  Schizophr Bull       Date:  2011-03-24       Impact factor: 9.306

7.  Mapping corticocortical structural integrity in schizophrenia and effects of genetic liability.

Authors:  Owen R Phillips; Keith H Nuechterlein; Robert F Asarnow; Kristi A Clark; Ryan Cabeen; Yaling Yang; Roger P Woods; Arthur W Toga; Katherine L Narr
Journal:  Biol Psychiatry       Date:  2011-05-14       Impact factor: 13.382

8.  Altered center-surround motion inhibition in schizophrenia.

Authors:  Yue Chen; Daniel Norton; Dost Ongur
Journal:  Biol Psychiatry       Date:  2008-01-22       Impact factor: 13.382

9.  Is motion perception deficit in schizophrenia a consequence of eye-tracking abnormality?

Authors:  L Elliot Hong; Kathleen A Turano; Hugh B O'Neill; Lei Hao; Ikwunga Wonodi; Robert P McMahon; Gunvant K Thaker
Journal:  Biol Psychiatry       Date:  2008-12-03       Impact factor: 13.382

10.  Effects of ketamine on brain function during smooth pursuit eye movements.

Authors:  M Steffens; B Becker; C Neumann; A M Kasparbauer; I Meyhöfer; B Weber; M A Mehta; R Hurlemann; U Ettinger
Journal:  Hum Brain Mapp       Date:  2016-11       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.